Breaking News

Financial Reports: Biogen Idec

April 25, 2013

MS franchise continues growth

Biogen Idec 1Q13

1Q Revenues: $1.4 billion (+10%)

1Q Earnings: $427 million (+41%)

Comments: Avonex sales rose 13% ($746 million), Tysabri rose 9% ($312 million), Fampyra was up 54% ($23 million) and Fumaderm was up 8% ($14 million). Rituxan revenues from its joint business arrangement fell 7% to $265 million.

blog comments powered by Disqus